Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients

British Journal of Psychiatry

Volumn 170, Issue MAY, 1997, Pages 422-425

  Franz, M ^a   Lis, S ^a   Pluddemann K ^a   Gallhofer, B ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SEDATIVE AGENT; TRANQUILIZER; ZOTEPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL LIFE; WELLBEING;

EID: 0031009205     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.170.5.422     Document Type: Article

References (14)

1. Awad, A. G. & Hogan, T. P. (1994) Subjective response to neuroleptics and quality of life - implications for treatment outcome. Acta Psychiatrica Scandinavica, 89 (suppl. 380), 27-32.
2. Dilling, H., Mombour, W. & Schmidt, M. H. (1991) Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V(F) (ed. Weltgesundheitsorganisation), pp. 103-107, Bern: Huber.
3. Franz, M. & Gallhofer, B. (1996) Befindlichkeit und Compliance: Klinische Beobachtungen unter Risperidon. Therapie-woche Neurologie Psychiatrie, 10, 951-954.
4. _, Plüddemann, K., Gruppe, H., et al (1996) Modifikation und Anwendung der Münchner Lebensqualitäts-Dimensionen-Liste bei schizophrenen Patienten, In Befunderhebung in der Psychiatrie: Negativsymptomatik. Lebensqualität und andere neue Entwicklungen (eds H. J. Möller, R. Engel & P. Hoff), pp. 103-111, Vienna: Springer.
5. Gelders, Y. G. (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. British Journal of Psychiatry, 155, 33-36.
6. Heinisch, M., Ludwig, M. & Bullinger, M. (1991) Psychometrische Testung der "Münchner Lebensqualitäts Dimensionen Liste (MLDL)". In Lebensqualität bei kardiovaskulären Erkrankungen (eds M. Bullinger, M. Ludwig & N. von Steinbüchel), pp. 73-90. Göttingen: Hogrefe.
7. Johnson, D. A.W. (1981) Studies of depressive symptoms in schizophrenia. The prevalence of depression and its possible causes. British Journal of Psychiatry, 139, 89-101.
8. Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-275.
9. Lehman, A. F. (1993) Convergent validation of quality of life assessments for persons with severe mental illnesses. Quality of Life Research, 2, 327-333.
10. Lieberman, J. A. (1993) Understanding the mechanism of action of atypical antipsychotic drugs. British Journal of Psychiatry, 163 (suppl. 22), 7-18.
11. Meltzer, H. Y. (1993) Dimensions of outcome with clozapine. British Journal of Psychiatry, 160 (suppl. 17), 46-53.
12. Naber, D., Hackl, C., Marzelli, B., et al (1992) Zur subjektiven Wirkung von Clozapin im Vergleich zu typischen Neuroleptika. In Pharmakologie und Klinik eines atypischen Neuroleptikums (eds D. Naber & F. Müller-Spahn), pp. 171-177. Stuttgart: Schattauer.
13. Saran, A. S. (1986) Use or abuse of antiparkinsonian drugs by psychiatric patients. Journal of Clinical Psychiatry, 47, 130-132.
14. Van Putten, T. & May, P. R. A. (1978) Akinetic depression in schizophrenia. Archives of General Psychiatry, 35, 1101-1107.